



# Presentation of results

## 3Q 2021



# Legal notice

---

This document and the information contained herein (unless otherwise indicated) have been prepared by Captor Therapeutics S.A. (the "Issuer") solely for informational purposes. For this notice, the presentation that follows shall mean and include the slides that follow, the oral presentation of the slides by the Issuer or any person on behalf of the Issuer, any question-and-answer session that follows the oral presentation, hard copies of this document, and any materials distributed at, or in connection with the presentation (collectively, the "Presentation"). By attending the meeting at which the Presentation is made, or by reading the Presentation, you will be deemed to have (i) agreed to all of the following restrictions and made the following undertakings and (ii) acknowledged that you understand the legal and regulatory sanctions attached to the misuse, disclosure or improper circulation of the Presentation.

The information contained in this Presentation may not be reproduced or redistributed in any way, in whole or in part, to any other person without the prior written consent of the Issuer. This Presentation does not purport to contain all the information that may be required by the recipient to assess the Issuer or its securities. The Issuer prepared this Presentation based on the information which it has and from sources believed to be reliable. To the extent available, the industry, market, and competitive position data contained in this Presentation come from official or third-party sources. There is no guarantee of the accuracy or completeness of such data.

This Presentation contains neither a complete nor a comprehensive financial or commercial analysis of the Issuer, nor does it present its position or prospects in a complete or comprehensive manner. The Issuer has prepared the Presentation with due care, however certain inconsistencies or omissions might have appeared in it. Therefore it is recommended that any person who intends to undertake any investment decision regarding any security issued by the Issuer shall only rely on information released as an official communication (i.e. current/periodic reports) in accordance with the legal and regulatory provisions.

This Presentation may contain certain forward-looking statements, forecasts, estimates, projections, and opinions ("Forward-looking Statements"). By their nature, Forward-looking Statements involve known and unknown risks, uncertainties, assumptions, and other factors because they relate to events and depend on circumstances that will occur in the future whether or not outside the control of the Issuer. No representation is made or will be made that any Forward-looking Statements will be achieved or will prove to be correct. Actual future results and operations could vary materially from the Forward-looking Statements. Similarly, no representation is given that the assumptions disclosed in this Presentation upon which Forward-looking Statements may be based are reasonable. The recipient acknowledges that circumstances may change and the contents of this Presentation may become outdated as a result. The assumptions included herein do not constitute profit forecasts or profit estimates.

No warranties or representations can be made as to the comprehensiveness or reliability of the information contained in this Presentation. Neither the Issuer nor its directors, managers, advisers or representatives of such persons shall bear any liability that might arise in connection with any use of this Presentation. Furthermore, no information contained herein constitutes an obligation or representation of the Issuer, its managers or directors, its shareholders, subsidiary undertakings, advisers or representatives of such persons.

Data contained in this Presentation is valid as of the day of its preparation. Consequently, this Presentation will not be subject to changes, updates or modifications to account for events which might occur after this day.

This Presentation does not constitute or form part of, and should not be construed as, an offer to sell or issue, or the solicitation of an offer to purchase, subscribe to, or acquire the Issuer or the Issuer's securities, or an inducement to enter into investment activity in any jurisdiction in which such offer, solicitation, inducement or sale would be unlawful before registration, exemption from registration or qualification under the securities laws of such jurisdiction. No part of this Presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. This presentation is not for publication, release, or distribution in any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction nor should it be taken or transmitted into such jurisdiction.

# Agenda

---

- KEY EVENTS IN 3Q'2021, INCLUDING MCL-1 ANNOUNCEMENT
- COMPANY STRATEGY & TEAM
- SUMMARY ECONOMIC AND FINANCIAL DATA
- APPENDIX

# 3Q'2021 – key take-aways

---

## BUSINESS in a BRIEF

Q3 2021

- **MCL-1** – break-through – announcement of the drug target
- **3** – active participation in two prestigious conferences: 4th Annual Targeted Protein Degradation (TPD) Summit, European Protein Degradation Congress and BioEurope partnering meeting
- **5** – projects in drug pipeline
- **7%\*** – increase in number of employees
- **+49%\*\*** (Q3'2021/Q3'2020) – increased R&D spending
- **236 M PLN** - available funding secured; cash burn fully in line with plans
- **BionInMed** – founding of Polish Association of Innovative Medical Biotechnology Companies
- **2023** – planned start date of clinical trials


\*Until 30.09.2021; employment contracts, mandate contracts and Board

\*\**(R&D spending and overheads)*

# KEY EVENTS in 3Q 2021

---

# MCL-1 – a high potential drug target



**\*References:**

DOI: [10.1016/j.blre.2020.100672](https://doi.org/10.1016/j.blre.2020.100672)

DOI: [10.1080/13543776.2019.1672661](https://doi.org/10.1080/13543776.2019.1672661)

DOI: [10.1016/j.pharmthera.2018.10.009](https://doi.org/10.1016/j.pharmthera.2018.10.009)

# Strong MCL-1 degradation and apoptosis *in vivo*

---

**Captor obtained and verified results showing that the Company's compounds potently degrade Induced Myeloid Leukaemia Cell Differentiation Protein (MCL-1) across a wide range of cancer cell lines.**

The results obtained demonstrate the following properties of Captor's degrader molecules:

- ❖ Induction of programmed cell death, apoptosis, *in vitro* in different haematological cancer and solid tumour cell lines
- ❖ Desired pharmacodynamic effects, including *in vivo* degradation of MCL-1 in tumour-bearing mice in a leukaemia model (MV4-11)
- ❖ Strong induction of apoptosis *in vivo* in an MV4-11 leukaemia model, as a consequence of the degradation of MCL-1

# Captor Therapeutics presents at the most important bio-tech meetings in the industry

CONFERENCES HELD

4TH ANNUAL  
TARGETED  
PROTEIN  
DEGRADATION  
(TPD) SUMMIT

Presentation in Boston (US) by Chief Scientific Officer Dr. Michal Walczak, entitled: "New Opportunities in Targeting Cancer Resistance Mechanisms with TPD". The presentation included the new research findings of Captor's MCL-1 breakthrough.

BIOEUROPE  
PARTNERING  
MEETING

**One to one presentations at the BioEurope Meeting** by CEO Dr. Tom Shepherd - one of the main international digital partnering meetings in the life science industry, over 20 individual meetings with **potential** big-pharma partners.

UPCOMING


JP Morgan Annual  
Health Care  
Conference

2nd TPD Europe  
Summit

BioEurope  
Spring 2022



# Company pipeline projects



\*Preclinical stage include IND-enabling studies

\*\*First in Human; at least 2 projects expected to enter Phase I by 2023

BID – Bi-functional Degradar; MG – Molecular Glue


# A growing team of accomplished professionals and significant research spending favour Captor's rapid development



**7%** increase in employees



Highly attractive **employee stock plan** for **all** employees



**49%** increase in-R&D operational costs (3Q'2021-3Q'2020)

**44%** - percentage of scientific staff with a PhD degree

**Additional Benefits** available for all the employees

**236 M PLN** funding secured for further research and development projects

Continual focus on acquiring **new talent** and

**internal development of skills**

# COMPANY STRATEGY

---

# Captor Therapeutics: an ideal pharmaceutical synergy between Poland and Switzerland

---



A globally connected pharmaceutical hub



Poland has highly qualified scientific staff




Combine international expertise in Switzerland with local talent in Poland



Access to experienced pharmaceutical industry professionals



Polish cost base allows capital efficient research



Leverage international pharma connections with Polish infrastructure



A window to international investors




EU and Polish government non-dilutive funding to aid the growth of research-based industries and infrastructure



Cost-effective research guided by a global perspective and led by industry experts



# Vision – become a world-leading drug discovery company based on targeted protein degradation



- ❖ Based in Wrocław (Poland) and Basel (Switzerland)
- ❖ Backed by private and non-dilutive public funds as well as funds raised in recent IPO
- ❖ Disruptive platform in drug discovery
- ❖ Five drug programs in large potential markets
- ❖ ~97 FTEs on board, almost half of them are PhD level specialists
- ❖ Joint experience from more than 11 leading international universities
- ❖ 1,100 m<sup>2</sup> of laboratory space equipped with state-of-the-art equipment

A global, highly qualified team:



# An experienced leadership team

The Company is distinguished by an experienced leadership team with significant experience and clear responsibilities in innovation, commercialization of biopharmaceutical projects, operations and finance

## MANAGEMENT BOARD



**Tom Shepherd, Ph.D.**

Chief Executive Officer

- Chief Executive Officer
- 30 years experience in Business Development and CEO in USA & Europe
- Led 12 licensing transactions resulting in over \$2.5 billion annual sales
- 6 private investment rounds and 3 IPOs.

### EDUCATION



### PREVIOUS EXPERIENCE



**Michal Walczak, Ph.D.**

Chief Scientific Officer

- Ph.D. ETH Zurich,
- Post-doc FMI Basel (Novartis Research Foundation) on targeted protein degradation
- 10 years experience in drug discovery and protein degradation

### EDUCATION



### PREVIOUS EXPERIENCE



**Radoslaw Krawczyk**

Chief Financial Officer

- Chief Financial Officer
- Finance & banking Warsaw School of Economics
- MBA Marseille Graduate School of Management
- 20 years in Financial Strategy
- 8 years in listed companies on WSE
- 2 IPOs

### EDUCATION



### PREVIOUS EXPERIENCE



## CO-FOUNDER



**Sylvain Cottens, Ph.D.**

Co – founder – SVP Chemistry

- Ph.D. EPFL Lausanne,
- Post-doc Caltech, USA
- Scientific expert and leader with 25+ years of experience from Novartis
- Co-inventor of Afinitor and co-developer of Gilemya (both blockbuster drugs)

### EDUCATION




### PREVIOUS EXPERIENCE



# Three pillars of growth

---



The continued development of the platform provides a continuous & sustainable flow of new drug pipeline projects as pipeline drugs are commercialized

Captor focuses on severe diseases where there are a lack of satisfactory treatments and significant commercial potential.


Partnership with Sosei Heptares, a Japanese biopharmaceutical company listed on the Tokyo Stock Exchange with a successful track record of drug development

# The Biotechnology industry continues to advance

## Targeted Protein Degradation (TPD) is a new chapter in the development of the Biotechnology industry

- In 2020 IPOs of biopharmaceutical companies raised \$73 billion, or 54% of all capital raised
- A clear upward trend in the area of equity investment
- A record value of signed agreements in 2020 (partnering, licensing and joint venture) with a cumulative potential of \$198.2 billion
- TPD drugs hold a promise of addressing unmet medical needs through targeting pathological proteins inaccessible to classical approaches

Value of equity raised in Biotech



Source: BioWorld



# SUMMARY ECONOMIC AND FINANCIAL DATA

---

# Selected financial data

## REVENUES AND FINANCIAL RESULTS (PLN thousands)

	Full 3Q of 2021	Full 3Q of 2020
Research and development income	2 707	-
Other operating income	15 620	14 712
Net loss	-21 670	- 11 101

## MAIN BALANCE SHEET ITEMS (PLN thousands)

	30/09/2021	31/12/2020
Current assets	138 602	13 246
Equity	132 940	-1 004

## GROUP INDICATORS (%)

	30/09/2021	31/12/2020
Total debt ratio <sup>1</sup>	10,57%	103,89
Long-term debt ratio <sup>2</sup>	24,93%	25,30
short-term debt ratio <sup>3</sup>	75,07%	74,70


<sup>1</sup> total liabilities/total assets

<sup>2</sup> long-term liabilities/total liabilities

<sup>3</sup> short-term liabilities/total liabilities

## Operating cost structure for 9M'2021:


- **56%** - R&D expenditure
- **22%** - Project overheads
- **22%** - General and administrative expenses\*  
(\*excluding the employee stock plan in the amount of PLN 7 346 thousands )



## Available funding secured

(PLN M; as of 30/09/2021):

- **130 mln PLN** – cash
- **106 mln PLN**– agreements with NCBR



# Strong balance sheet and investments as foundation for further development

## HIGHLY QUALIFIED PERSONNEL

7%\* employment increase

1.

Data as of 30/09/2021

Number of employees	97
Number of research workers	80
Percentage of scientists with PhD	44%

## TANGIBLE FIXED ASSETS

e. g. PLN 4 M – new spectrometer

2.

- ❖ Fixed assets as at 30/09/2021 amounted to PLN 9,7 M, most of which is a hi-tech laboratory equipment.

## FINANCIAL RESOURCES

from IPO and NCBR grants


3.

- ❖ PLN 236 M, as of 30/09/2021

# APPENDIX

---

# Stages of the research & development process



# Selected financial data

(data in thous. PLN)

## INTERIM CONDENSED CONSOLIDATED STATEMENT OF PERFORMANCE AND OTHER COMPREHENSIVE INCOME

	01.01.2021- 30.09.2021	01.01.2020- 30.09.2020
Research and development income	2 707	-
Cost of services sold	482	-
Gross profit (loss) on sales	2 225	-
Operating profit (loss)	-20 898	-10 718
Profit (loss) before tax	-21 670	-11 101
Net profit (loss)	-21 670	-11 101
Number of shares	4 127 972	3 590 000
Net profit (loss) per share (in PLN/EUR)	-5,25	-3,09

## INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	30.09.2021	31.12.2020
Non-current assets	10 046	12 533
Current assets	138 602	13 246
Equity	132 940	-1 004
Non-current liabilities	3 916	6 777
Current liabilities	11 792	20 006

## INTERIM CONDENSED CONSOLIDATED CASH FLOW STATEMENT

	01.01.2021- 30.09.2021	01.01.2020- 30.06.2020
Net cash flows from operating activities	-22 855	4 488
Net cash flows from investing activities	-333	-148
Net cash flow from financing activities	142 592	-3 361



**Captor Therapeutics S.A**

ul. Duńska 11  
54-427 Wrocław, Poland



**Captor Therapeutics GmbH**

Gewerbestrasse 24  
4123 Allschwil, Switzerland


IR Contact:

Marta Świącicka

[m.swiecicka@captortherapeutics.com](mailto:m.swiecicka@captortherapeutics.com)

Media and IR Contact:

[captortherapeutics@pov.pl](mailto:captortherapeutics@pov.pl)



## Projects are co-financed by the European Regional Development Fund:

---

Discovery and development of a new clinical drug candidate for the eradication of cancer stem cell in the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor

(POIR.01.01.01-00-0740/19)

Discovery and development of non-toxic ligase ligands and their application in the treatment of autoimmunological diseases

(POIR.01.01.01-00-0741/19-00)

Inducing apoptosis with small molecules as therapeutic intervention in multiple severe malignancies

(POIR.01.01.01-00-0956/17-01)

Discovery and development of first-in-class of small molecule degrader as a drug candidate for the treatment of colorectal cancer

(POIR.01.02.00-00-0073/18-00)

Application of targeted protein degradation technology in the treatment of psoriasis and rheumatoid arthritis

(POIR.01.02.00-00-0079/18-00)

